Abbott (ABT) is recalling all the powder formulas, including Similac, Alimentum and EleCare, that were manufactured at Abbott Nutrition’s Sturgis, Michigan, facility due to the presence of Cronobacter sakazakii and Salmonella Newport infections.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The step has been taken based on complaints of four infant illnesses from three states, one of which has died. The U.S. Food and Drug Administration is investigating the matter and has initiated an onsite inspection at the facility.
Notably, the regulator said to have found several positive Cronobacter sakazakii results from environmental samples. Also, a review of the firm’s internal records reflects the presence of the germ in the environment and that Abbott destroyed some products due to the presence of Cronobacter.
The company said that it did not detect the presence of germs in any distributed product, however, it still continues to test. Also, it assured that several quality checks are run before a batch of infant formula is sent out.
Meanwhile, retained samples related to the three complaints about Cronobacter sakazakii and the sample related to the complaint for Salmonella Newport have been tested negative.
Dividend History
Abbott’s dividend history remains impressive. ABT has been increasing its quarterly dividend once each year in January with the trend continuing in 2022 as well. The company has raised its quarterly common stock dividend to $0.47, up 4.4% from the previous payout, which is payable on February 15.
Positive Sentiment
TipRanks’ Stock Investors tool shows that investors currently have a Very Positive stance on Abbott, as 14.6% of investors on TipRanks increased their exposure to ABT stock over the past 30 days.
Download the TipRanks mobile app now
To find good ideas for stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Read full Disclaimer & Disclosure
Related News:
Ventas Posts Wider-Than-Expected Q4 Loss
Shake Shack Declines 11% Despite Lower-Than-Expected Q4 Loss
Universal Music Signs Deal to Develop NFT Collections
